Evidence map›Paper›PMID 42383358›Full record

ArticleThe Journal of clinical investigation2026

SGLT2 inhibitors enhance ketogenesis by acting as allosteric activators of the mitochondrial enzyme HMGCS2.

Abdualrahman Mohammed Abdualkader, Xiaobei Li, Yiming Yin, Chenhao Bai, Parisa Pourfarziani, Jiaheng Guan, Sora Kwon, Kyoung-Han Kim, Rami Al Batran

Abstract read
In one paragraph

Article in The Journal of clinical investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Abdualrahman Mohammed AbdualkaderFaculty of Pharmacy, Université de Montréal, Montréal, Quebec, Canada.
Xiaobei LiFaculty of Pharmacy, Université de Montréal, Montréal, Quebec, Canada.
Yiming YinFaculty of Pharmacy, Université de Montréal, Montréal, Quebec, Canada.
Chenhao BaiFaculty of Pharmacy, Université de Montréal, Montréal, Quebec, Canada.
Parisa PourfarzianiFaculty of Pharmacy, Université de Montréal, Montréal, Quebec, Canada.
Jiaheng GuanFaculty of Pharmacy, Université de Montréal, Montréal, Quebec, Canada.
Sora KwonUniversity of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Kyoung-Han KimUniversity of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Rami Al BatranFaculty of Pharmacy, Université de Montréal, Montréal, Quebec, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SGLT2 inhibitors boost ketone production by directly activating a liver enzyme, revealing a new mechanism that may contribute to their heart and kidney benefits.

Indexed as

Hydroxymethylglutaryl-CoA SynthaseKetone BodiesMitochondriaSodium-Glucose Transporter 2 InhibitorsAllosteric RegulationAnimalsHumansMiceSodium-Glucose Transporter 2Hydroxymethylglutaryl-CoA SynthaseKetone BodiesSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsDiabetesEndocrinologyFatty acid oxidationGlucose metabolismMetabolism

Identifiers

PMID42383358
PMCPMC13318103

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.